TEIJIN PHARMA LIMITED | News Release

Latest News Release

Jun. 03, 2025	Navepegritide Designated as an Orphan Drug by Japan’s Ministry of Health, Labor and Welfare
Dec. 13, 2024	Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Hypoparathyroidism Treatment
Apr. 10, 2024	Teijin Pharma Grants Global Exclusive License to Bioprojet to Develop a New Orexin Receptor 2 Agonist Investigational Candidate for Narcolepsy
Feb. 13, 2024	Teijin and Axcelead to Determine the Name of Drug Discovery Research JV
Nov. 29, 2023	Notice Concerning a Decision on the Licensing Agreement related to the Three Hormone Therapy Drugs for Rare Endocrine Diseases
Jul. 03, 2023	Teijin and Axcelead to Establish Drug Discovery Research Joint Venture
Mar. 06, 2023	Teijin Pharma Grants Global Exclusive Licens for Investigational Small Molecule Candidate in Kidney Disease
Apr. 05, 2022	Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery
Feb. 01, 2022	Anti-Tau Antibody created by Teijin Pharma and developed by Merck & Co., Inc., Kenilworth NJ USA Enters Clinical Development
Jun. 23, 2021	Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A